Identification of michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity

Antioxidants and Redox Signaling

Volumn 19, Issue 11, 2013, Pages 1149-1165

  Gan, Fei Fei ^a   Kaminska, Kamila K ^a   Yang, Hong ^a   Liew, Chin Yee ^a   Leow, Pay Chin ^a   So, Choon Leng ^a   Tu, Lan N L ^a   Roy, Amrita ^a   Yap, Chun Wei ^a   Kang, Tse Siang ^a   Chui, Wai Keung ^a   Chew, Eng Hui ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 DIPHENYL PENT 1 EN-3 ONE; 1,7 DIPHENYL HEPT 3 EN 5 ONE; AMIDE; ANTINEOPLASTIC AGENT; CHALCONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HERBACEOUS AGENT; ISOBUTYLAMIDE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OXIDOREDUCTASE INHIBITOR; SHOGAOL; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; ZERUMBONE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL LYSATE; CELL STRAIN HCT116; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG SYNTHESIS; ECHINACEA PURPUREA; ENZYME ACTIVITY; ENZYME INHIBITION; GINGER; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; MICHAEL ADDITION; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; WESTERN BLOTTING; ZANTHOXYLUM; ZINGIBER ZERUMBET;

AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; RATS; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84884687097     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4909     Document Type: Article

References (53)

1. Arnér ES and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102-6109, 2000.
2. Arnér ES, Sarioglu H, Lottspeich F, Holmgren A, and Böck A. High-level expression in Escherichia coli of selenocysteinecontaining rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and coexpression with the selA, selB and selC genes. J Mol Biol 292: 1003-1016, 1999. (Pubitemid 29481713)
3. Arscott LD, Gromer S, Schirmer RH, Becker K, and Williams CH, Jr. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc Natl Acad Sci USA 94: 3621-3626, 1997.
4. Becker K, Herold-Mende C, Park JJ, Lowe G, and Schirmer RH. Human thioredoxin reductase is efficiently inhibited by (2,2¢:6¢,2¢ ¢-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J Med Chem 44: 2784-2792, 2001. (Pubitemid 32879719)
5. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, and Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16: 3459-3466, 1996. (Pubitemid 27084998)
6. Biterova EI, Turanov AA, Gladyshev VN, and Barycki JJ. Crystal structures of oxidized and reduced mitochondrial thioredoxin reductase provide molecular details of the reaction mechanism. Proc Natl Acad Sci USA 102: 15018-15023, 2005. (Pubitemid 41513327)
7. Cai W, Zhang L, Song Y, Wang B, Zhang B, Cui X, Hu G, Liu Y, Wu J, and Fang J. Small molecule inhibitors of mammalian thioredoxin reductase. Free Radic Biol Med 52: 257-265, 2012.
8. Casini A and Messori L. Molecular mechanisms and proposed targets for selected anticancer gold compounds. Curr Top Med Chem 11: 2647-2660, 2011.
9. Cenas N, Nivinskas H, Anusevicius Z, Sarlauskas J, Lederer F, and Arnér ES. Interactions of quinones with thioredoxin reductase: a challenge to the antioxidant role of the mammalian selenoprotein. J Biol Chem 279: 2583-2592, 2004. (Pubitemid 38114244)
10. Cheng Q, Sandalova T, Lindqvist Y, and Arnér ES. Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J Biol Chem 284: 3998-4008, 2009.
11. Chew EH, Lu J, Bradshaw TD, and Holmgren A. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J 22: 2072-2083, 2008. (Pubitemid 351811483)
12. Chew EH, Nagle AA, Zhang Y, Scarmagnani S, Palaniappan P, Bradshaw TD, Holmgren A, and Westwell AD. Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Free Radic Biol Med 48: 98-111, 2010.
13. Fang J and Holmgren A. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo. J Am Chem Soc 128: 1879-1885, 2006. (Pubitemid 43277327)
14. Fang J, Lu J, and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280: 25284-25290, 2005. (Pubitemid 40934623)
15. Fritz-Wolf K, Kehr S, Stumpf M, Rahlfs S, and Becker K. Crystal structure of the human thioredoxin reductasethioredoxin complex. Nat Commun 2: 383, 2011.
16. Fritz-Wolf K, Urig S, and Becker K. The structure of human thioredoxin reductase 1 provides insights into C-terminal rearrangements during catalysis. J Mol Biol 370: 116-127, 2007. (Pubitemid 46817572)
17. Gan FF, Nagle AA, Ang X, Ho OH, Tan SH, Yang H, Chui WK, and Chew EH. Shogaols at proapoptotic concentrations induce G(2)/M arrest and aberrant mitotic cell death associated with tubulin aggregation. Apoptosis 16: 856-867, 2011.
18. Gromer S, Arscott LD, Williams CH, Jr., Schirmer RH, and Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273: 20096-20101, 1998. (Pubitemid 28377564)
19. Gromer S, Urig S, and Becker K. The thioredoxin system-from science to clinic. Med Res Rev 24: 40-89, 2004.
20. Hashemy SI, Ungerstedt JS, Zahedi Avval F, and Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281: 10691-10697, 2006. (Pubitemid 43855490)
21. Hu R, Zhou P, Peng YB, Xu X, Ma J, Liu Q, Zhang L, Wen XD, Qi LW, Gao N, and Li P.6-shogaol induces apoptosis in human hepatocellular carcinoma cells and exhibits antitumor activity in vivo through endoplasmic reticulum stress. PLoS One 7: e39664, 2012.
22. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, and Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275: 90-94, 1997. (Pubitemid 27020316)
23. Kahlos K, Soini Y, Saily M, Koistinen P, Kakko S, Paakko P, Holmgren A, and Kinnula VL. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 95: 198-204, 2001. (Pubitemid 32477237)
24. Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K, and Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 11: 8425-8430, 2005. (Pubitemid 41746957)
25. Kitayama T, Okamoto T, Hill RK, Kawai Y, Takahashi S, Yonemori S, Yamamoto Y, Ohe K, Uemura S, and Sawada S. Chemistry of zerumbone.1. Simplified isolation, conjugate addition reactions, and a unique ring contracting transannular reaction of its dibromide. J Org Chem 64: 2667-2672, 1999.
26. Kundu JK, Na HK, and Surh YJ. Ginger-derived phenolic substances with cancer preventive and therapeutic potential. Forum Nutr 61: 182-192, 2009.
27. Ladenstein R, Epp O, Bartels K, Jones A, Huber R, and Wendel A. Structure analysis and molecular model of the selenoenzyme glutathione peroxidase at 2.8 A resolution. J Mol Biol 134: 199-218, 1979.
28. Lee SR, Kim JR, Kwon KS, Yoon HW, Levine RL, Ginsburg A, and Rhee SG. Molecular cloning and characterization of a mitochondrial selenocysteine- containing thioredoxin reductase from rat liver. J Biol Chem 274: 4722-4734, 1999.
29. Lu J, Chew EH, and Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci USA 104: 12288-12293, 2007. (Pubitemid 47206130)
30. Lu J and Holmgren A. Thioredoxin system in cell death progression. Antioxid Redox Signal 17: 1738-1747, 2012.
31. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, and Holmgren A. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66: 4410-4418, 2006.
32. Murakami A, Takahashi D, Kinoshita T, Koshimizu K, Kim HW, Yoshihiro A, Nakamura Y, Jiwajinda S, Terao J, and Ohigashi H. Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha,betaunsaturated carbonyl group is a prerequisite. Carcinogenesis 23: 795-802, 2002. (Pubitemid 34567518)
33. Papp LV, Lu J, Holmgren A, and Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9: 775-806, 2007. (Pubitemid 46919583)
34. Powis G, Wipf P, Lynch SM, Birmingham A, and Kirkpatrick DL. Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther 5: 630-636, 2006.
35. Prasannan R, Kalesh KA, Shanmugam MK, Nachiyappan A, Ramachandran L, Nguyen AH, Kumar AP, Lakshmanan M, Ahn KS, and Sethi G. Key cell signaling pathways modulated by zerumbone: role in the prevention and treatment of cancer. Biochem Pharmacol 84: 1268-1276, 2012.
36. Prast-Nielsen S, Dexheimer TS, Schultz L, Stafford WC, Cheng Q, Xu J, Jadhav A, Arnér ES, and Simeonov A. Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay. Free Radic Biol Med 50: 1114-1123, 2011.
37. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, and Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142: 46-51, 2003. (Pubitemid 36934520)
38. Ren B, Huang W, Akesson B, and Ladenstein R. The crystal structure of seleno-glutathione peroxidase from human plasma at 2.9 A resolution. J Mol Biol 268: 869-885, 1997. (Pubitemid 27229170)
39. Rozell B, Hansson HA, Luthman M, and Holmgren A. Immunohistochemical localization of thioredoxin and thioredoxin reductase in adult rats. Eur J Cell Biol 38: 79-86, 1985. (Pubitemid 15045722)
40. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signalregulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998. (Pubitemid 28221195)
41. Sandalova T, Zhong L, Lindqvist Y, Holmgren A, and Schneider G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci USA 98: 9533-9538, 2001. (Pubitemid 32769338)
42. Singh DV and Misra K. Curcuminoids as inhibitors of thioredoxin reductase: a receptor based pharmacophore study with distance mapping of the active site. Bioinformation 4: 187-192, 2009.
43. Soini Y, Kahlos K, Napankangas U, Kaarteenaho-Wiik R, Saily M, Koistinen P, Paaakko P, Holmgren A, and Kinnula VL. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757, 2001. (Pubitemid 32708645)
44. Sun QA, Kirnarsky L, Sherman S, and Gladyshev VN. Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc Natl Acad Sci USA 98: 3673-3678, 2001. (Pubitemid 32249829)
45. Urig S and Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 16: 452-465, 2006. (Pubitemid 44780136)
46. Wang L, Yang Z, Fu J, Yin H, Xiong K, Tan Q, Jin H, Li J, Wang T, Tang W, Yin J, Cai G, Liu M, Kehr S, Becker K, and Zeng H. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Free Radic Biol Med 52: 898-908, 2012.
47. Wang X, Zhang J, and Xu T. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol Appl Pharmacol 218: 88-95, 2007. (Pubitemid 46026846)
48. Wipf P, Hopkins TD, Jung JK, Rodriguez S, Birmingham A, Southwick EC, Lazo JS, and Powis G. New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead. Bioorg Med Chem Lett 11: 2637-2641, 2001. (Pubitemid 32823373)
49. Witte AB, Anesta° l K, Jerremalm E, Ehrsson H, and Arnér ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinumcontaining anticancer compounds. Free Radic Biol Med 39: 696-703, 2005. (Pubitemid 41112110)
50. Yan C, Siegel D, Newsome J, Chilloux A, Moody CJ, and Ross D. Antitumor indolequinones induced apoptosis in human pancreatic cancer cells via inhibition of thioredoxin reductase and activation of redox signaling. Mol Pharmacol 81: 401-410, 2012.
51. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, and Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281: 13005-13008, 2006. (Pubitemid 43855208)
52. Yoo MH, Xu XM, Carlson BA, Patterson AD, Gladyshev VN, and Hatfield DL. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS One 2: e1112, 2007.
53. Zhong L, Arnér ES, Ljung J, Aslund F, and Holmgren A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J Biol Chem 273: 8581-8591, 1998. (Pubitemid 28176132)